发明名称 Insulin derivative formulations for pulmonary delivery
摘要 Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
申请公布号 US8900555(B2) 申请公布日期 2014.12.02
申请号 US200712374891 申请日期 2007.07.27
申请人 Nektar Therapeutics 发明人 Kuo Mei-Chang;Eldon Michael;Yuan Yiqiong
分类号 A61K9/12;A61K9/00;A61K38/28 主分类号 A61K9/12
代理机构 代理人 Wilson Mark A.
主权项 1. An aerosolized formulation, comprising: a first insulin derivative having an isoelectric point (p1) ranging from about 6.5 to about 7.5, wherein the first insulin derivative is glargine insulin; a second insulin or insulin derivative; Trehalose; Leucine; a liquid carrier, which is water, ethanol, ethanol-water, or saline; and a precipitating agent, which is a free cation selected from at least one of zinc, copper, cobalt, iron, manganese, vanadium, cadmium, magnesium, calcium, and barium; wherein the first insulin derivative and the precipitating agent are dissolved in the liquid carrier; wherein the molar ratio of the precipitating agent to the first insulin derivative is from about 1:3 to about 5:1; wherein the first insulin derivative is present in an amount of from about 20 weight % to about 99 weight %.
地址 San Francisco CA US